4- Thursday Pharmacotherapy News – 8th April

1 – Strategies to overcome drug resistance using SHP2 inhibitors

• Encoded by PTPN11, the SHP2 (Src homology-2 domain-containing protein tyrosine phosphatase-2) is widely recognized as a carcinogenic phosphatase.
• Studies have proved the therapeutic potential of SHP2 inhibitor in overcoming drug resistance of kinase inhibitors and programmed cell death-1 (PD-1) blockade.
• This study reviews the structure, function and small molecular inhibitors of SHP2, and highlight recent progress in overcoming drug resistance using SHP2 inhibitor.

Source: ScienceDirect

2 – Can nanoparticles and nano‒protein interactions bring a bright future for insulin delivery?

• Insulin therapy plays an essential role in the treatment of diabetes mellitus.
• However, frequent injections required to effectively control the glycemic levels lead to substantial inconvenience and low patient compliance.
• This study aims to provide an insight into the advance and flaws of various NPs-based insulin delivery systems.
• Particularly, an interesting discussion on nano‒protein interactions and its potentials for developing novel insulin delivery systems is initiated.

Source: ScienceDirect

3 – Hospitalization of mild cases of community-acquired pneumonia decreased more than severe ones during the COVID-19 epidemic

• The epidemic of the coronavirus disease 2019 (COVID-19) has affected the entire health care systems.
• The aim of this study was to assess the impact of the COVID-19 epidemic on the number and severity of cases for community-acquired pneumonia (CAP).
• This study showed a significant reduction in the number of inpatient cases for CAP during the COVID-19 epidemic.
• The milder cases showed a greater decrease in the year-over-year ratio of the number of inpatient cases.

Source: ScienceDirect

4- COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update

• For patients with multiple sclerosis (MS), the pandemic has been of particular concern because of the co-morbidities of this disease as well as the disease-modifying therapies (DMTs) used in its management.
• This study reports on 272 cladribine tablets (CladT)-treated patients who acquired COVID-19
• Of the total evaluable cohort, 40 (15%) experienced serious COVID-19
• Median onset of COVID-19 from recent preceding CladT treatment course was 162 days
• 51% of patients were recovered/recovering at time of analysis.

Source: ScienceDirect

5 – Pharmacists self-perceived role competence in prevention and containment of COVID-19: A cross-sectional study

• The increased need for prioritized infection prevention and control (IPC) activities for the prevention and containment of COVID-19 is pivotal and timely in preventing harm caused by the COVID-19 pandemic.
• This study aimed to assess pharmacists’ perceived role competence to perform frontline roles during the COVID-19 pandemic.
• Pharmacists are well-positioned as access points to care and can potentially play a significant role in the containment of the COVID-19 outbreak by delivering advanced clinical and public health services.

Source: ScienceDirect

6 – Anti-Inflammatory treatment of COVID-19 pneumonia with tofacitinib alone or in combination with dexamethasone is safe and possibly superior to dexamethasone as a single agent

• This study aims to explore the survival benefit of tofacitinib in addition to dexamethasone in hospitalized patients treated for COVID-19 pneumonia.
• The in-patient treatment of COVID-19 pneumonia has rapidly evolved. The addition of dexamethasone has made a relevant improvement on survival.
• They found that adding tofacitinib based anti-inflammatory therapy to a treatment regimen including dexamethasone in COVID-19 pneumonia seems to have potential benefit of improving survival when compared to dexamethasone alone.

Source: ScienceDirect

• Read more from FADIC Blog, with many articles with evidence based articles.
• Learn More Through FADIC® – Online Programs & Mini-Courses.
• Listen Now to FADIC Podcast focusing on varieties of pharmacist perspectives in specialties.
• Read More Now about FADIC Pharmacy Events to get more Experience.

Course Copyrights:

All Courses is meant for SINGLE user use only.
If more than one person acceced this course, they will be BLOCKED Forever.

Why FADIC 2021 Pharmacotherapy Daily News (FNN) ?

• It helps to keep up with the literature!
• Provide you with the Updated with the latest in your clinical practice. Wherever you are, and Whenever you need!
• Help you to share in the advance in clinical career. In addition to adding an impressive image to the pharmacists all-around!

Subscribe to FADIC 2021 Pharmacotherapy Daily News (FNN), for a publication of E-News

Read & Download FNN Issue 8 of April 2020 FNN News